Free Trial

Benitec Biopharma (BNTC) Competitors

Benitec Biopharma logo
$11.18 -0.73 (-6.13%)
Closing price 04:00 PM Eastern
Extended Trading
$11.25 +0.07 (+0.63%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BNTC vs. ELVN, GPCR, BGM, PRAX, ARDX, AVDL, SANA, DYN, AKBA, and COLL

Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), BGM Group (BGM), Praxis Precision Medicines (PRAX), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Akebia Therapeutics (AKBA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

Benitec Biopharma vs. Its Competitors

Benitec Biopharma (NASDAQ:BNTC) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec BiopharmaN/AN/A-$21.75M-$1.51-7.40
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.04

Enliven Therapeutics' return on equity of -31.84% beat Benitec Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -38.26% -35.71%
Enliven Therapeutics N/A -31.84%-30.09%

In the previous week, Enliven Therapeutics had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 9 mentions for Enliven Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.83 beat Enliven Therapeutics' score of 0.54 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Benitec Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Benitec Biopharma presently has a consensus price target of $26.00, indicating a potential upside of 132.56%. Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 94.34%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Benitec Biopharma is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Benitec Biopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

Benitec Biopharma beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTC vs. The Competition

MetricBenitec BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$293.48M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-7.4021.1828.1120.03
Price / SalesN/A337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book2.398.368.655.90
Net Income-$21.75M-$55.19M$3.25B$258.66M
7 Day Performance1.27%5.89%4.20%2.23%
1 Month Performance-15.05%17.63%10.83%12.77%
1 Year Performance22.45%5.10%34.67%19.36%

Benitec Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTC
Benitec Biopharma
1.6245 of 5 stars
$11.18
-6.1%
$26.00
+132.6%
+28.5%$293.48MN/A-7.4020
ELVN
Enliven Therapeutics
2.6313 of 5 stars
$21.87
-3.5%
$41.20
+88.4%
-8.6%$1.11BN/A-11.3950Insider Trade
GPCR
Structure Therapeutics
2.952 of 5 stars
$18.13
-5.8%
$76.17
+320.1%
-49.6%$1.10BN/A-20.84136Positive News
BGM
BGM Group
N/A$10.63
-5.8%
N/AN/A$1.10B$25.10M0.00298High Trading Volume
PRAX
Praxis Precision Medicines
2.3787 of 5 stars
$55.16
+2.4%
$94.11
+70.6%
+1.6%$1.10B$8.55M-5.15110
ARDX
Ardelyx
4.0215 of 5 stars
$4.42
+0.2%
$10.89
+146.4%
-22.4%$1.06B$361.71M-20.0990
AVDL
Avadel Pharmaceuticals
1.9959 of 5 stars
$10.98
+1.4%
$18.33
+67.0%
-31.0%$1.05B$169.12M-40.6770
SANA
Sana Biotechnology
3.1805 of 5 stars
$4.44
-4.1%
$9.17
+106.5%
-16.2%$1.04BN/A-5.05380
DYN
Dyne Therapeutics
3.7782 of 5 stars
$9.17
+1.7%
$40.63
+343.0%
-78.9%$1.03BN/A-2.55100
AKBA
Akebia Therapeutics
3.8294 of 5 stars
$3.84
-0.5%
$6.75
+75.8%
+161.2%$1.01B$184.91M-18.28430Positive News
COLL
Collegium Pharmaceutical
4.4834 of 5 stars
$30.91
-0.9%
$43.75
+41.5%
-6.5%$1.00B$631.45M25.34210News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:BNTC) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners